BioSpace News Archive

Vertex Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for SYMKEVI® in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis aged 12 and older who either have two copies of the F508del mutation in the...

CVS Health Corporation will be holding a conference call on Wednesday, August 8, 2018, at 8:30 a.m. (ET) with analysts and investors to discuss its second quarter financial results.

- Net sales of $2.008 billion for the second quarter represent an increase of 3.0% over the prior year period, and an increase of 1.0% on a constant currency basis - Diluted EPS for the second quarter were $0.90 as reported, flat when compared to the prior year period - Adjusted diluted EPS for the second quarter were $1.92, a decrease of 7.7% from the prior year period - The Company updates full-year 2018 revenue guidance

Mirvetuximab Soravtansine Granted Fast Track Designation by FDA

Exact Imaging, the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced today that it has become a UroGPO Imaging Partner.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2018.

Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the second quarter ended June 30, 2018

Nutrex Hawaii®, Inc. is proud to announce that its BioAstin® Hawaiian Astaxanthin® has received the highly prestigious United States Pharmacopeia (USP®) Verified Mark.

Endo International plc announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck’s INVANZ® (ertapenem for injection)

European Commission Decision Expected in September